Literature DB >> 11265292

Engineered properties and assays for human DNase I mutants.

C Q Pan1, D V Sinicropi, R A Lazarus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11265292     DOI： 10.1385/1-59259-233-3:309

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


× No keyword cloud information.
  3 in total

1.  Using Pulmozyme DNase treatment in lentiviral vector production.

Authors:  Aaron Shaw; Daniela Bischof; Aparna Jasti; Aaron Ernstberger; Troy Hawkins; Kenneth Cornetta
Journal:  Hum Gene Ther Methods       Date:  2012-02       Impact factor: 2.396

2.  The in vivo expression of actin/salt-resistant hyperactive DNase I inhibits the development of anti-ssDNA and anti-histone autoantibodies in a murine model of systemic lupus erythematosus.

Authors:  Anthony P Manderson; Francesco Carlucci; Peter J Lachmann; Robert A Lazarus; Richard J Festenstein; H Terence Cook; Mark J Walport; Marina Botto
Journal:  Arthritis Res Ther       Date:  2006-04-10       Impact factor: 5.156

3.  Bi-directional SIFT predicts a subset of activating mutations.

Authors:  William Lee; Yan Zhang; Kiran Mukhyala; Robert A Lazarus; Zemin Zhang
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.